Singh Biotechnology: Fighting Cancer, Eye Disease with Small Antibodies That Can Cross Cell Membranes Interview with:

Dr. Saundra Singh M.D., Ph.D. Founder & CEO/President Singh Biotechnology 

Dr. Singh

Dr. Saundra Singh M.D., Ph.D.
Founder & CEO/President
Singh Biotechnology
 What is the mission of Singh Biotechnology?  

  • Our mission is to develop medicine and therapeutics that dramatically improve and save the lives of people worldwide suffering from diseases, including cancer. What are the advantages of the Single Domain Antibody technology?

  • The average human antibody is 150 Kd in size and works on the outside of the cell. The advantage of the single domain nanobody is that it is significantly smaller, in fact, it is one-tenth the size (approximately 15 Kd) of the human antibody. A smaller nanobody is more useful therapeutically because, unlike many cancer drugs currently on the market, it can penetrate the blood-brain barrier, the blood-retina barrier, and the cell membrane. Moreover, our SBT-100 drug has been shown to be non-toxic in animal models. How does SBT-100 target pancreatic cancer and osteosarcoma?  

  • SBT-100 shuts off the “master switch” to the genes that tell cancer cells to grow and proliferate. This is a powerful approach to stopping cancer in its tracks. Would you briefly discuss the findings of one of your publications?

  • SBT-100 could potentially treat many indications, one of them being uveitis, a form of eye inflammation that leads to pain and blurriness. In Frontiers of Immunology, the National Institute of Health and National Eye Institute called SBT-100 “curative and non-toxic.” Would you discuss your partnership with Music Beats Cancer?

Music Beats Cancer is a nonprofit that supports biotech innovators working on solutions for cancer. The organization operates a charitable crowdfunding platform that enables companies like ours to raise a round of non-dilutive funding from the charitable donations of the crowd. We hope to raise $25K to support our next product development milestones. Learn more about our campaign with Music Beats Cancer here.

Would you comment on the status of funding for biotech innovation and cancer research?

  • While the overall biotech investments have grown each year, there is a conspicuous and unfortunate funding gap for seed/pre-seed biotech startups. Early-stage companies are notoriously risky, expensive, time-consuming, and often fail. Therefore, funding streams in the form of grants or non-dilutive funds, rather than investment dollars, are imperative to boost the success of innovative solutions for fighting disease. Is there anything else you would like to add?

  • We encourage other early-stage biotechs to engage Music Beats Cancer if they seek capital to support proof of principle studies. Sharing biotech ideas with the public is key to helping us advance the war on cancer.[wysija_form id=”3″][last-modified] The information on is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

Last Updated on February 8, 2022 by Marie Benz MD FAAD